Want to see IN:ARVEE full AI Analyst Report?
Top Page
Arvee Laboratories (India) Ltd.
(ARVEE)
Select Model
Select Model
Rating:58Neutral
Price Target:
₹219.00
▼(-9.62% Downside)
Action:Reiterated
Date:09/10/26
The score is primarily held back by weakening cash flow and volatile revenue trends despite a very strong, low-leverage balance sheet. Technicals are supportive due to a clear uptrend, but the stock appears overbought, and a high P/E with no stated dividend support further limits the overall rating.
Positive Factors
Low leverage and growing equity
Very low leverage and steadily rising equity reduce financial fragility and preserve capacity to fund operations or strategic investment without relying heavily on lenders. This financial flexibility is a durable advantage if operating conditions remain uneven over the next several quarters.
Negative Factors
Weak recent cash generation
Recent operating and free cash flow weakness indicates that reported profitability is not currently translating into cash generation. Persistent cash absorption could reduce funding flexibility, increase reliance on the strong balance sheet, and constrain investment if it continues over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and growing equity
Very low leverage and steadily rising equity reduce financial fragility and preserve capacity to fund operations or strategic investment without relying heavily on lenders. This financial flexibility is a durable advantage if operating conditions remain uneven over the next several quarters.
Read all positive factors
Arvee Laboratories (India) Ltd. (ARVEE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.14B
Dividend YieldN/A
Average Volume (3M)6.54K
Price to Earnings (P/E)57.1
Beta (1Y)1.30
Revenue Growth16.67%
EPS Growth194.60%
CountryIN
Employees65
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)3.68
Shares Outstanding11,020,000
10 Day Avg. Volume7,412
30 Day Avg. Volume6,541
Financial Highlights & Ratios
PEG Ratio3.35
Price to Book (P/B)4.37
Price to Sales (P/S)4.69
P/FCF Ratio-50.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Arvee Laboratories (India) Ltd. Business Overview & Revenue Model
Company Description
Arvee Laboratories (India) Ltd., established in 2012 and headquartered in Ahmedabad, India, specializes in the production and distribution of various specialized chemicals throughout the country. The company's product line includes a range of poly...
Arvee Laboratories (India) Ltd. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
82
Very Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 412.59M | 315.14M | 384.87M | 303.42M | 612.76M | 403.27M |
| Gross Profit | 141.40M | 111.68M | 121.63M | 41.49M | 173.09M | 138.08M |
| EBITDA | 55.80M | 31.98M | 42.69M | 35.78M | 86.34M | 61.90M |
| Net Income | 40.51M | 25.26M | 21.47M | 10.52M | 41.19M | 25.74M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 432.57M | 381.58M | 381.99M | 386.85M | 386.85M |
| Cash, Cash Equivalents and Short-Term Investments | 32.82M | 32.82M | 49.06M | 18.65M | 8.92M | 31.08M |
| Total Debt | 0.00 | 11.13M | 10.33M | 10.00M | 10.00M | 31.31M |
| Total Liabilities | -337.88M | 95.30M | 68.97M | 90.85M | 106.23M | 147.43M |
| Stockholders Equity | 337.88M | 337.88M | 312.61M | 291.14M | 280.62M | 239.42M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -29.02M | -17.35M | 10.78M | 14.45M | 16.52M |
| Operating Cash Flow | 0.00 | -694.00K | 1.19M | 36.64M | 29.29M | 40.16M |
| Investing Cash Flow | 0.00 | 2.17M | -17.91M | -21.63M | -12.58M | 592.61K |
| Financing Cash Flow | 0.00 | 802.00K | 333.00K | -1.88M | -24.17M | -60.51M |
Arvee Laboratories (India) Ltd. Technical Analysis
Positive
242.32
Price Trends
164.47
Positive
164.66
Positive
168.71
Positive
Market Momentum
5.73
Negative
75.07
Negative
58.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ARVEE, the sentiment is Positive. The current price of 242.32 is above the 20-day moving average (MA) of 171.84, above the 50-day MA of 164.47, and above the 200-day MA of 168.71, indicating a bullish trend. The MACD of 5.73 indicates Negative momentum. The RSI at 75.07 is Negative, neither overbought nor oversold. The STOCH value of 58.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ARVEE.
Arvee Laboratories (India) Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | ₹3.30B | 20.60 | ― | 1.36% | 3.55% | -21.35% | |
62 Neutral | ₹2.51B | 13.61 | ― | 0.13% | 12.41% | 51.78% | |
58 Neutral | ₹2.14B | 57.14 | ― | ― | 16.67% | 194.60% | |
57 Neutral | ₹1.99B | 24.47 | ― | 1.39% | 11.94% | 15.20% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹3.65B | 24.55 | ― | 0.16% | 16.52% | 224.79% | |
47 Neutral | ₹714.67M | 43.69 | ― | 1.64% | -20.79% | ― |
* General Sector Average
IN:ARVEE
Arvee Laboratories (India) Ltd.
210.29
53.44
34.07%
IN:AKSHARCHEM
AksharChem India Ltd.
431.85
155.05
56.02%
IN:PODDARMENT
Poddar Pigments Limited
295.90
16.76
6.00%
IN:SRD
Shankar Lal Rampal Dye-Chem Ltd.
38.85
-38.00
-49.45%
IN:TAINWALCHM
Tainwala Chemicals & Plastics (India) Ltd
213.00
1.99
0.94%
IN:VINEETLAB
Vineet Laboratories Ltd.
37.09
8.93
31.71%
Arvee Laboratories (India) Ltd. Corporate Events
Arvee Laboratories Closes Trading Window Ahead of June Quarter Results
Jun 27, 2026
Arvee Laboratories (India) Ltd. has announced the closure of its trading window for company securities from July 1, 2026, until two trading days after the publication of financial results for the quarter ended June 30, 2026. This measure applies t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.